The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

The elevated risk of Parkinson’s disease in patients with diabetes might be mitigated depending
on the type of drugs prescribed to treat diabetes. Population data for risk of Parkinson’s …

Introduction Pain is a common and disabling non-motor symptom of Idiopathic Parkinson's
disease (PD) but its underlying pathophysiological mechanisms are not well understood. …

Background The phenotypic spectrum of adenylyl cyclase 5 (ADCY5)‐related disease has
expanded considerably since the first description of the disorder in 1978 as familial essential …

Background Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson's
disease (PD), but its effect on disease progression is not well understood. Objective The …

Introduction Parkinson’s disease (PD) is a common neurodegenerative disorder with substantial
morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 …

Disease-modifying treatments are currently being trialled in multiple system atrophy. Approaches
based solely on clinical measures are challenged by heterogeneity of phenotype and …

Parkinson’s disease is a chronic, neurodegenerative disease, which manifests with a
mixture of motor, cognitive and behavioural symptoms. Levodopa is the most effective …

The recent validation of the α-synuclein seed amplification assay as a biomarker with high
sensitivity and specificity for the diagnosis of Parkinson’s disease has formed the backbone …

Introduction: While deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been
extensively used for more than 20 years in Parkinson’s disease (PD), the optimal area of …